Evolus, Inc. raised earnings guidance for the full year 2023. For the year, the company now expects total net revenues to be between $194 million and $198 million from $185 Million to $195 Million, representing year-over-year growth of greater than 30% and magnitudes above the estimated growth rate of the aesthetic neurotoxin market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.51 USD | +0.48% | -7.95% | +18.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.80% | 780M | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Raises Earnings Guidance for the Full Year 2023